Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Net Income: 2009-2024

Historic Net Income for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to -$465.9 million.

  • Madrigal Pharmaceuticals' Net Income fell 3.88% to -$111.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$286.0 million, marking a year-over-year increase of 44.86%. This contributed to the annual value of -$465.9 million for FY2024, which is 24.69% down from last year.
  • Madrigal Pharmaceuticals' Net Income amounted to -$465.9 million in FY2024, which was down 24.69% from -$373.6 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Net Income registered a high of -$202.3 million during FY2020, and its lowest value of -$465.9 million during FY2024.
  • In the last 3 years, Madrigal Pharmaceuticals' Net Income had a median value of -$373.6 million in 2023 and averaged -$378.3 million.
  • Data for Madrigal Pharmaceuticals' Net Income shows a maximum YoY slumped of 141.03% (in 2020) over the last 5 years.
  • Over the past 5 years, Madrigal Pharmaceuticals' Net Income (Yearly) stood at -$202.3 million in 2020, then declined by 19.66% to -$242.1 million in 2021, then fell by 21.99% to -$295.4 million in 2022, then fell by 26.50% to -$373.6 million in 2023, then dropped by 24.69% to -$465.9 million in 2024.